Endoxifen for the treatment of bipolar I disorder
US11291640B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 9, 2021 |
| Grant date | Apr 5, 2022 |
| Priority date | — |
| Expiry date | Apr 9, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/2833
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for maintaining a therapeutically effective concentration of endoxifen for the treatment of patient with bipolar I disorder is provided. The method includes administering to the patient a dose of 2 mg to 16 mg of endoxifen citrate in an enteric coated tablet once per day for at least 21 days. Further, the said method provides a desirable in-vivo plasma profile. The therapeutic dose monitoring is not required in a patient undergoing the said treatment. Furthermore, the method provides a significant improvement in mania assessed by the YMRS and the MADRS scores in patient undergoing the said treatment. Furthermore, the method as provides an early response time of the treatment in at least 2 days and remission time that is not more than 4 days in patient undergoing the said treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.